Compare EVLV & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVLV | CDNA |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 988.3M | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | EVLV | CDNA |
|---|---|---|
| Price | $6.71 | $19.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $9.13 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 2.9M | 750.2K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | $136,501,000.00 | ★ $357,998,000.00 |
| Revenue This Year | $41.16 | $14.11 |
| Revenue Next Year | $14.71 | $11.75 |
| P/E Ratio | ★ N/A | $15.51 |
| Revenue Growth | ★ 43.16 | 14.46 |
| 52 Week Low | $2.64 | $10.96 |
| 52 Week High | $8.91 | $25.95 |
| Indicator | EVLV | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 54.20 |
| Support Level | $6.51 | $19.01 |
| Resistance Level | $7.30 | $20.61 |
| Average True Range (ATR) | 0.33 | 0.71 |
| MACD | 0.02 | -0.22 |
| Stochastic Oscillator | 22.16 | 18.43 |
Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.